IFN Gamma Specific Neutra™ Antibody Products

Are you struggling with inconsistent antibody efficacy or off-target effects in immune-mediated disease research? Creative Biolabs' IFN gamma specific Neutra™ antibody products leverage proprietary humanized antibody engineering to ensure high-affinity neutralization, enabling precise targeting of IFN gamma-driven pathologies and accelerating therapeutic development.

Introduction to IFN gamma

Interferon gamma (IFN gamma), a pleiotropic cytokine produced primarily by activated T cells and natural killer (NK) cells, is central to both innate and adaptive immunity. Its functions span immune surveillance, macrophage activation, and Th1 differentiation, making it a critical mediator in host defense and inflammatory responses.

• Basic Information

IFN gamma is encoded by a single gene on human chromosome 12 and functions as a homodimeric glycoprotein. Unlike type I interferons, IFN gamma signals through a unique receptor complex (IFNGR1/IFNGR2) to regulate over 200 genes, including those governing antigen presentation and microbial killing. Its expression is tightly regulated, with dysregulation linked to autoimmune diseases, chronic infections, and cancer.

• Structural Insights

The IFN gamma monomer comprises six alpha-helices arranged in a compact globular fold. Dimerization via antiparallel helix interactions creates a symmetrical structure essential for receptor binding. Key epitopes for neutralizing antibodies cluster near the receptor-binding interface, enabling selective blockade of downstream signaling.

• Signaling Pathways

IFN gamma activates the JAK-STAT1 pathway, inducing phosphorylation of STAT1 homodimers that translocate to the nucleus to drive pro-inflammatory gene transcription. Cross-talk with TLR and NF-κB pathways amplifies inflammatory cascades, while negative regulators like SOCS1 fine-tune responses to prevent immunopathology.

Fig.1 IFN-gamma (IFN-γ) canonical signaling pathway.¹

• Disease Associations

Overproduction of IFN gamma underpins autoimmune disorders such as rheumatoid arthritis and lupus, where it promotes tissue damage via unchecked macrophage activation. Conversely, IFN gamma deficiency predisposes individuals to severe intracellular infections (e.g., mycobacterial diseases) and compromises tumor immunosurveillance.

Applications of IFN gamma Neutralizing Antibodies

• Therapeutic Intervention in Autoimmune Diseases

Neutralizing antibodies mitigate IFN gamma-driven pathologies in autoimmune conditions. Clinical trials demonstrate efficacy in reducing disease flares in lupus nephritis by inhibiting macrophage hyperactivation and renal inflammation.

• Combating Chronic Infections

In chronic viral infections (e.g., hepatitis C), anti-IFN gamma antibodies moderate excessive inflammation, preserving tissue integrity while maintaining antiviral defenses. This balanced approach improves patient outcomes in co-infection models.

• Oncology: Modulating Tumor Immunity

IFN gamma's dual role in promoting tumor immunity and immune evasion is context-dependent. Neutralizing antibodies help dismantle immunosuppressive tumor microenvironments in melanoma models, enhancing checkpoint inhibitor efficacy.

• Diagnostic and Biomarker Development

High-sensitivity ELISA kits incorporating these antibodies enable early detection of IFN gamma spikes in cytokine release syndrome, guiding timely therapeutic interventions.

Anti-IFN gamma Antibodies

Neutralizing antibodies against IFN gamma are engineered to bind epitopes critical for receptor engagement, effectively disrupting signal transduction. Creative Biolabs' antibodies exhibit sub-nanomolar affinity validated in functional assays (e.g., STAT1 phosphorylation inhibition) and cross-react with primate orthologs for translational studies. Applications include:

- Therapeutic Development: Blocking IFN gamma in cytokine storm syndromes.

- Diagnostic Tools: Quantifying IFN gamma in autoimmune disease biomarkers.

- Mechanistic Research: Elucidating IFN gamma's role in tumor microenvironment modulation.

Creative Biolabs' IFN gamma specific Neutra™ antibody products offer rigorously validated tools to dissect and target IFN gamma pathways across research applications.

Contact our scientific team today to explore custom solutions for your project and accelerate breakthroughs in immunotherapy.

REFERENCE

1. Castro, Flávia, et al. "Interferon-gamma at the crossroads of tumor immune surveillance or evasion." Frontiers in immunology 9 (2018): 847. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2018.00847